Biosimilars set to revolutionize global drug development industry, says report

30 September 2014

Intellectual Property and Science business of Thomson Reuters today announced the release of Biosimilars: A Global Perspective of a New Market – Opportunities, Threats and Critical Strategies 2014, which provides critical insights for companies and regions interested in maintaining a strong position and moving ahead of the competition in the biosimilars space.

It is rare to see a new business segment emerge in any market, but this is what is happening within the biopharmaceutical development industry, according to the new report compiled by Thomson Reuters BioWorld.

More than 700 therapies in pipelines

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >